Journal article
A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis
Journal of the American Academy of Dermatology, v 63(6), pp 984-990
04 Oct 2010
PMID: 20889234
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background : Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma.
Objective : We wished to test whether topical hypericin was an effective, safe, and well-tolerated therapy for patch or plaque phase mycosis fungoides and for plaque psoriasis.
Methods : We conducted a phase II placebo-controlled clinical study in patients who had either patch or plaque phase mycosis fungoides or plaque type psoriasis vulgaris. Representative lesions were treated twice weekly for 6 weeks with topically applied hypericin or placebo followed 24 hours later by exposure to visible light at 8 to 20 J/cm2.
Results : After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective.
Limitations : The clinical trial involved a small number of patients.
Conclusions : Overall, the data from this study support the conclusion that topical hypericin/visible light photodynamic therapy is an effective and well-tolerated alternative to standard psoralen plus ultraviolet A treatment of these disorders.
Metrics
Details
- Title
- A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis
- Creators
- Alain H. Rook - University of PennsylvaniaGary S. Wood - University of Wisconsin SystemMadeleine Duvic - The University of Texas MD Anderson Cancer CenterEric C. Vonderheid - Drexel University, Philadelphia, PennsylvaniaAlfonso Tobia - BioPharmaBernard Cabana - BioPharma
- Publication Details
- Journal of the American Academy of Dermatology, v 63(6), pp 984-990
- Publisher
- Mosby, Inc
- Number of pages
- 7
- Grant note
- Vimrx Inc Department of Veterans Affairs
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000284968100004
- Scopus ID
- 2-s2.0-78650298649
- Other Identifier
- 991021864001604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Dermatology